知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

206 条记录 (耗时 0.031 秒)

    SUPPOSITORY DELIVERY DEVICE
    111.
    发明申请
    SUPPOSITORY DELIVERY DEVICE 有权
    支持交付设备

    公开(公告)号：US20090223855A1

    公开(公告)日：2009-09-10

    申请号：US12041771

    申请日：2008-03-04

    申请人： Karen D. HIGGINS ,  Kathleen K. PIEPER

    发明人： Karen D. HIGGINS ,  Kathleen K. PIEPER

    IPC分类号： A61J1/00

    CPC分类号： A61F13/55185 ,  A61F13/266 ,  A61F13/55175 ,  A61M31/007 ,  Y10S424/15 ,  Y10S514/966

    摘要： A suppository delivery device that allows for the insertion of a suppository without having contact with the suppository or rectum. The suppository delivery device includes a stabilizer to which the suppository is mounted, and a package, which protects the user's hands and fingers from the suppository and rectum and prevents germs from contacting the suppository before being inserted into the rectum.

    摘要翻译： 一种栓剂递送装置，其允许插入栓剂而不与栓剂或直肠接触。 栓剂递送装置包括安装栓剂的稳定剂和包装，其保护使用者的手和手指免于栓剂和直肠，并防止细菌在插入直肠之前接触栓剂。

    Liquid suppository composition of diclofenac sodium
    118.
    发明授权
    Liquid suppository composition of diclofenac sodium 失效
    液体栓剂组合物双氯芬酸钠

    公开(公告)号：US06488954B1

    公开(公告)日：2002-12-03

    申请号：US09938797

    申请日：2001-08-24

    申请人： Sung June Yoon ,  Jei Man Ryu ,  Jae Hee Jung ,  Su Jin Cho

    发明人： Sung June Yoon ,  Jei Man Ryu ,  Jae Hee Jung ,  Su Jin Cho

    IPC分类号： A61F902

    CPC分类号： A61K31/196 ,  A61K9/0031 ,  A61K9/02 ,  Y10S424/15 ,  Y10S514/966

    摘要： The present invention relates to a liquid suppository composition comprising diclofenac sodium, poloxamer and at least one polymer select from the group consisting of polyethylene oxide and polyvinylpyrrolidone. The composition provides the advantages of. (1) a feel of foreign matter or discomfort does not occur when the composition is rectally administered; and (2) administration is easy and after rectal administration, the composition is neither leaked out from the anus nor shifted into the end of large intestine.

    摘要翻译： 本发明涉及包含双氯芬酸钠，泊洛沙姆和至少一种选自聚环氧乙烷和聚乙烯吡咯烷酮的聚合物的液体栓剂组合物。 该组合物提供了优点。 （1）组合物直肠给药时不会发生异物感或不适感; 和（2）管理容易，经直肠给药后，组合物既不会从肛门渗出也不会移入大肠的末端。

    Use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses
    119.
    发明申请
    Use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses 失效
    使用细菌噬菌体相关的裂解酶进行各种疾病的预防和治疗

    公开(公告)号：US20020127212A1

    公开(公告)日：2002-09-12

    申请号：US09866106

    申请日：2001-05-25

    发明人： Vincent Fischetti ,  Lawrence Loomis

    IPC分类号： A61K038/43 ,  A61K009/68

    CPC分类号： A61K9/00 ,  A61K38/00 ,  A61L15/38 ,  A61L15/46 ,  C12N9/503 ,  Y02A50/473 ,  Y02A50/481 ,  Y10S424/15 ,  Y10S514/924 ,  Y10S514/937 ,  Y10S514/944 ,  Y10S514/948

    摘要： A method for the prophylactic and therapeutic treatment of bacterial infections is disclosed which comprises the treatment of an individual with an effective amount of a lytic enzyme composition specific for the infecting bacteria, with the lytic enzyme comprising an effective amount of lytic enzyme, wherein the lytic enzyme is in an environment having a pH which allows for activity of said lytic enzyme; and a carrier for delivering said lytic enzyme. This method, and composition can be used for the treatment of upper respiratory infections, skin infections, wounds, and burns, vaginal infections, eye infections, intestinal disorders and dental problems.

    摘要翻译： 公开了一种用于预防和治疗细菌感染的方法，其包括用有效量的感染细菌特异性的溶解酶组合物治疗个体，溶解酶包含有效量的溶解酶，其中溶解酶 酶处于具有允许所述溶解酶的活性的pH的环境中; 和用于递送所述裂解酶的载体。 该方法和组合物可用于治疗上呼吸道感染，皮肤感染，伤口和烧伤，阴道感染，眼睛感染，肠道疾病和牙齿问题。

    Treatment of hyperproliferative disorders
    120.
    发明授权
    Treatment of hyperproliferative disorders 有权
    治疗过度增生性疾病

    公开(公告)号：US06352844B1

    公开(公告)日：2002-03-05

    申请号：US09342019

    申请日：1999-06-28

    申请人： Barry J. Maurer ,  Myles Cabot ,  C. Patrick Reynolds

    发明人： Barry J. Maurer ,  Myles Cabot ,  C. Patrick Reynolds

    IPC分类号： C12N1509

    CPC分类号： A61K45/06 ,  A61K31/07 ,  A61K31/165 ,  A61K31/535 ,  A61K31/70 ,  Y10S424/15 ,  A61K2300/00

    摘要： A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-generating retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) ceramide degredation inhibitor, such as compounds selected from the group consisting of (i) glucosylceramide synthesis inhibitors, (ii) sphingosine-1-phosphate synthesis inhibitors, and (iii) protein kinase C inhibitors. A preferred glucosyl ceramide synthesis inhibitor is 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingosine-1-phosphate synthesis inhibitor is D-erythro-N,N-dimethylsphingosine. A preferred protein kinase C inhibitor is L-threo-dihydrosphingosine.

    摘要翻译： 一种治疗需要这种治疗的受试者的过度增殖性疾病的方法，包括给所述受试者组合施用治疗有效量的：（a）产生神经酰胺的类视黄醇例如芬维A胺或其药学上可接受的盐; 和（b）至少一种（和在某些实施方案中至少两种）神经酰胺降解抑制剂，例如选自（i）葡糖基神经酰胺合成抑制剂，（ii）鞘氨醇-1-磷酸合成抑制剂和（iii） ）蛋白激酶C抑制剂。 优选的葡糖基神经酰胺合成抑制剂是1-苯基-2-棕榈酰氨基-3-吗啉代-1-丙醇。 优选的鞘氨醇-1-磷酸合成抑制剂是D-赤式-N，N-二甲基鞘氨醇。 优选的蛋白激酶C抑制剂是L-苏式 - 二氢鞘氨醇。